title: [Clinical studies of long-term administration of OK-432 in patients with gynecologic cancer].
abstract: The clinical value of OK-432 treatments, was evaluated in 215 patients with various types of gynecologic cancer. Five KE OK-432 was administrated by intramuscular injection every other day for up to 5 years, unless severe side-effects were observed. The 5-year survival rate was determined in 51 patients in the OK-432 group and 93 patients in the control group. The survival rate in the OK-432 group was significantly higher in the cervical cancer patients in stages III and IV than in the control group, at from 20 to 29 months and from 37 to 42 months. These results indicated that long period administration of OK-432 might improve the survival rate in patients with gynecologic cancer, especially in those with advanced cervical cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Shuto Hospital, Yamaguchi.
authors.forename: T
authors.initials: T
authors.lastname: Mano
authors.forename: K
authors.initials: K
authors.lastname: Kawamoto
authors.forename: T
authors.initials: T
authors.lastname: Miyake
authors.forename: T
authors.initials: T
authors.lastname: Torigoe
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001688:Biological Products / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005833:Genital Neoplasms, Female / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D009367:Neoplasm Staging; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy
chemical_list: D001688:Biological Products; D010844:Picibanil